Latest Breaking News On - Rachel vann - Page 3 : comparemela.com

New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks

New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJeffreyw shermanTerry smithTina venturaRachel vannWk kellogg eye centerAmerican association of clinical endocrinology annual meetingDepartment of ophthalmologyEuropean group on grave orbitopathyProduct communicationsExchange commissionEndocrine society annual meetingDrug administrationUniversity of michigan medical schoolEndocrine societyAmerican association

Horizon Therapeutics plc: Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA (inebilizumab-cdon)

Analysis in The Journal of Neurology, Neurosurgery and Psychiatry demonstrate the direct effect of UPLIZNA on levels of sNFL and sGFAP, two key biomarkers strongly associated with NMOSD attacks

United statesNeuroimmunol neuroinflammRachel vannOrhan aktasKristina pattersonTina venturaProduct communicationsExchange commissionDepartment of neurologyExpanded disability status scaleMedical facultyNeuromyelitis optica spectrum disorderHepatitisb virusProgressive multifocal leukoencephalopathyFull prescribing informationUnited states securities

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA®

DUBLIN (BUSINESS WIRE) Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease (TED) and low clinical activity score (CAS), which is a measure of disease act.

United statesErin linnihanElizabethhz thompsonTina venturaMaggie fairchildRachel vannJapan pharmaceuticalsDrug administrationProduct communicationsEuropean group on grave orbitopathyDevices agencyHorizon therapeuticsThyroid eye diseaseMedical devices agencyJapan registryClinical trials

Horizon Therapeutics (HZNP) to Present UPLIZNA Data in Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics (HZNP) to Present UPLIZNA Data in Neuromyelitis Optica Spectrum Disorder
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRachel vannMandeep kaurNeuroimmunol neuroinflammNeuromyelitis opticaTina venturaEuropean commissionProduct communicationsDrug administrationAmerican academy of neurologyBrazilian health regulatory agencyExchange commissionAnnual meetingDisease activityTrial receiving inebilizumab treatmentImmunosuppression treatment

Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration

Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of Thyroid Eye Disease Horizon Therapeutics plc (Nasdaq: HZNP) today announced

United statesTina venturaRachel vannTim walbertEuropean group on grave orbitopathyExchange commissionDrug administrationProduct communicationsEuropean group on graveThyroid eyeEye diseaseThyroid eye diseaseInflammatory bowel diseaseFull prescribing informationUnited states securitiesThyroid associated